Many large tertiary hospitals purchase "do not accept imported products"!

The China Government Procurement Network recently released the Public Tender Notice for the Medical Magnetic Resonance Imaging System Project of the Cancer Hospital of the Chinese Academy of Medical Sciences (hereinafter referred to as the "Announcement".

The China Government Procurement Network recently released the Public Tender Notice for the Medical Magnetic Resonance Imaging System Project of the Cancer Hospital of the Chinese Academy of Medical Sciences (hereinafter referred to as the "Announcement".

The Cancer Hospital of the Chinese Academy of Medical Sciences, as a well-known large-scale tertiary hospital in China, enjoys a high reputation in the field of oncology, and its every move is regarded as a benchmark in the industr.

In recent years, policies such as the "14th Five-Year Plan for Pharmaceutical Industry Development", "14th Five-Year Plan for Bio-economic Development", "14th Five-Year Plan for National Health" and "14th Five-Year Plan for Medical Equipment Industry Development" have all been Clearly encourage the high-quality development of the pharmaceutical industry, support domestic enterprises to accelerate innovation and realize domestic substitution, and promote industrial transformation and upgradin.

Focusing on unmet clinical needs, guided by clinical value, the market in all fields such as drugs, medical devices, and consumables has grown rapidl.

The industry generally believes that with the gradual deepening of the reform of the medical insurance payment system and the in-depth implementation of the national procurement policy with volume, the in-hospital market, once occupied by imported drugs and medical devices, is bound to encounter more and more problems under the policy support and the demand for cost reduction and cost contro.

Will "domestic limited" become a trend? Will "domestic limited" become a trend?

Medical equipment consumables usher in localization in an all-round way

Pharmaceutical equipment consumables fully usher in localization Pharmaceutical equipment consumables fully usher in localization

The Cancer Hospital of the Chinese Academy of Medical Sciences is the location of the National Cancer Clinical Research Center, the National Cancer Standardized Diagnosis and Treatment Quality Control Center, and the former National Drug Clinical Research Center certified by the State Food and Drug Administratio.

The public bidding stated that only domestic products were accepted, and it was clearly pointed out that this project was not a government purchase servic.

In fact, in addition to the Cancer Hospital of the Chinese Academy of Medical Sciences, many top domestic medical institutions have recently begun to purchase domestically produced medical device product.
"Limited domestic production" is by no means an exception:

In May 2021, the Sichuan Government Procurement Network issued two procurement announcements in successio.
The Affiliated Hospital of North Sichuan Medical College will purchase a batch of medical equipment in 2021, a total of 2,117 sets of domestic medical equipment, with a total budget of 742 millio.
In the procurement requirements, it is clearly required that the equipment and the reagents and chips to be configured in the later stage must be all domestically produce.

In May 2021, the Sichuan Government Procurement Network issued two procurement announcements in successio.
The Affiliated Hospital of North Sichuan Medical College will purchase a batch of medical equipment in 2021, a total of 2,117 sets of domestic medical equipment, with a total budget of 742 millio.
In the procurement requirements, it is clearly required that the equipment and the reagents and chips to be configured in the later stage must be all domestically produce.

In October 2021, Peking Union Medical College Hospital entrusted China Machinery Import & Export (Group) C.
, Lt.
to issue a tender announcement to purchase inspection equipment for key discipline development, including high performance liquid chromatography tandem mass spectrometer, inductively coupled plasma mass spectrometer, fully automatic flow cytometer Fluorescence diagnostic system, nucleic acid quality analyzer, et.
, with a total budget of 25 million yua.
Note: Only domestic equipment is purchase.

In October 2021, Peking Union Medical College Hospital entrusted China Machinery Import & Export (Group) C.
, Lt.
to issue a tender announcement to purchase inspection equipment for key discipline development, including high performance liquid chromatography tandem mass spectrometer, inductively coupled plasma mass spectrometer, automatic flow cytometry Fluorescence diagnostic system, nucleic acid quality analyzer, et.
, with a total budget of 25 million yua.
Note: Only domestic equipment is purchase.

In January 2022, the Health and Health Commission of Yexian County, Pingdingshan City, Henan Province budgeted 16 million to purchase 1,333 medical products for several health centers, including: computer X-ray tomography scanners, mobile DR, biochemical analyzers, anesthetics, monitors , ambulances, bedding kits, stretchers, ventilators and other 36 kinds of medical equipment, divided into 15 procurement packages in tota.
The announcement made it clear that imported products would not be accepte.

In January 2022, the Health and Health Commission of Yexian County, Pingdingshan City, Henan Province budgeted 16 million to purchase 1,333 medical products for several health centers, including: computer X-ray tomography scanners, mobile DR, biochemical analyzers, anesthetics, monitors , ambulances, bedding kits, stretchers, ventilators and other 36 kinds of medical equipment, divided into 15 procurement packages in tota.
The announcement made it clear that imported products would not be accepte.

In May 2022, the Third Affiliated Hospital of Sun Yat-Sen University had a budget of 23 million to purchase DSA and supporting equipmen.
In the third item of the label, it indicated that the purchased products were non-imported product.

In May 2022, the Third Affiliated Hospital of Sun Yat-Sen University had a budget of 23 million to purchase DSA and supporting equipmen.
In the third item of the label, it indicated that the purchased products were non-imported product.

Industry experts said that for a long time in the past, most large public hospitals in China were seldom willing to purchase domestic consumables and equipment due to complex reasons and economic factors, which to a certain extent hit the research and development and innovation of domestic medical device companie.
positivity and confidenc.

Industry experts said that for a long time in the past, most large public hospitals in China were seldom willing to purchase domestic consumables and equipment due to complex reasons and economic factors, which to a certain extent hit the research and development and innovation of domestic medical device companie.
positivity and confidenc.

Today, large tertiary hospitals have begun to purchase domestic products more activel.
The confidence of "not accepting imported products" comes from the support of procurement policies on the one hand, and on the other hand, a number of excellent domestic medical equipment enterprises have begun to emerge in Chin.
Some products are from Technology and quality have also been gradually recognized, and the process of domestic substitution has been accelerated:

Today, large tertiary hospitals have begun to purchase domestic products more activel.
The confidence of "not accepting imported products" comes from the support of procurement policies on the one hand, and on the other hand, a number of excellent domestic medical equipment enterprises have begun to emerge in Chin.
Some products are from Technology and quality have also been gradually recognized, and the process of domestic substitution has been accelerated:

As early as 2004 and 2005, MicroPort Medical and Lepu Medical successively launched domestic drug-eluting coronary stents, and gradually competed with multinational giants such as Johnson & Johnson, Medtronic, and Boston Scientific to occupy the domestic coronary stent marke.
At present, domestic brands Lepu, MicroPort and Jiwei together account for more than 70% of the market share of the cardiac stent marke.

As early as 2004 and 2005, MicroPort Medical and Lepu Medical successively launched domestic drug-eluting coronary stents, and gradually competed with multinational giants such as Johnson & Johnson, Medtronic, and Boston Scientific to occupy the domestic coronary stent marke.
At present, domestic brands Lepu, MicroPort and Jiwei together account for more than 70% of the market share of the cardiac stent marke.

In 2017, the ultra-clear light guide PET-CT independently developed by United Imaging entered the largest single hospital in Japan - Fujita Health University Hospital in Japa.
This is the first Chinese high-end medical equipment to enter the Japanese marke.

In 2017, the ultra-clear light guide PET-CT independently developed by United Imaging entered the largest single hospital in Japan - Fujita Health University Hospital in Japa.
This is the first Chinese high-end medical equipment to enter the Japanese marke.

Mindray Medical, the leader in the field of domestic medical equipment, has all independent intellectual property rights and more than 960 patented technologies, filling the gap in domestic scientific research and development, and creating a number of "firsts" in Chin.
The market share of life information and support business such as monitors, ventilators, defibrillators, anesthesia machines, infusion pumps, and light towers has become the first in Chin.

Mindray Medical, the leader in the field of domestic medical equipment, has all independent intellectual property rights and more than 960 patented technologies, filling the gap in domestic scientific research and development, and creating a number of "firsts" in Chin.
The market share of life information and support business such as monitors, ventilators, defibrillators, anesthesia machines, infusion pumps, and light towers has become the first in Chin.

The General Office of the State Council previously issued the "Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry", which requires that domestically produced equipment must be purchased in principle, and the allocation of domestically produced equipment in public medical institutions should be gradually improve.
After the country has set the tone, many provinces have also issued relevant policies to further restrict imports; at the same time, driven by the DRG payment reform policy, hospitals have also shifted their resources to cost-effective domestic brands out of cost consideration.

The General Office of the State Council previously issued the "Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry", which requires that domestically produced equipment must be purchased in principle, and the allocation of domestically produced equipment in public medical institutions should be gradually improve.
After the country has set the tone, many provinces have also issued relevant policies to further restrict imports; at the same time, driven by the DRG payment reform policy, hospitals have also shifted their resources to cost-effective domestic brands out of cost consideration.

Taking Guangdong Province as an example, in May 2021, the Guangdong Provincial Medical Insurance Bureau issued the "Letter on the Opinions of the 1116th Representative of the Fourth Session of the Thirteenth National People's Congress of Guangdong Province on Suggesting Co-organization Opinions", pointing out that it will establish and improve medical insurance payment standards and centralized procurement of medical consumable.
The collaborative mechanism supports the development and use of domestic high-quality medical consumables and promotes the development of the domestic medical consumables industry by formulating medical insurance payment standards for selected and non-selected varieties of medical consumables in centralized procuremen.

Taking Guangdong Province as an example, in May 2021, the Guangdong Provincial Medical Insurance Bureau issued the "Letter on the Opinions of the 1116th Representative of the Fourth Session of the Thirteenth National People's Congress of Guangdong Province on Suggesting Co-organization Opinions", pointing out that it will establish and improve medical insurance payment standards and centralized procurement of medical consumable.
The collaborative mechanism supports the development and use of domestic high-quality medical consumables and promotes the development of the domestic medical consumables industry by formulating medical insurance payment standards for selected and non-selected varieties of medical consumables in centralized procuremen.

Today, China has become the second largest market in the global medical device marke.
New technologies, new materials, new products and new formats in the domestic medical device field are emerging one after another, and the scale benefits of China's medical device industry have shown explosive growt.

Today, China has become the second largest market in the global medical device marke.
New technologies, new materials, new products and new formats in the domestic medical device field are emerging one after another, and the scale benefits of China's medical device industry have shown explosive growt.

In addition, due to the high cost-effectiveness of domestic medical devices, it has a greater competitive advantage in seizing the market share of imported products, especially in the fields where domestic products are matur.
overall market shar.

In addition, due to the high cost-effectiveness of domestic medical devices, it has a greater competitive advantage in seizing the market share of imported products, especially in the fields where domestic products are matur.
overall market shar.

022

Procurement with volume continues to deepen

Purchasing with volume continues to deepen Purchasing with volume continues to deepen

Domestic substitution impacts the market structure

Domestic substitution impacts the market pattern Domestic substitution impacts the market pattern

Today, China's centralized procurement has achieved normalization and institutionalization, and achieved good social benefit.
In January 2022, at the executive meeting of the State Council, it was decided that the normalized and institutionalized procurement of drugs and high-value medical consumables will be carried out in a centralized manner to further reduce the medical burden on patient.

Today, China's centralized procurement has achieved normalization and institutionalization, and achieved good social benefit.
In January 2022, at the executive meeting of the State Council, it was decided that the normalized and institutionalized procurement of drugs and high-value medical consumables will be carried out in a centralized manner to further reduce the medical burden on patient.

In February of this year, Chen Jinfu, deputy director of the National Medical Insurance Bureau, said at the State Council's regular policy briefing that the procurement of medical consumables will be further extended to spinal consumables, thereby basically realizing the main body coverage of orthopedic consumables, the largest segment of consumable.

In February of this year, Chen Jinfu, deputy director of the National Medical Insurance Bureau, said at the State Council's regular policy briefing that the procurement of medical consumables will be further extended to spinal consumables, thereby basically realizing the main body coverage of orthopedic consumables, the largest segment of consumable.

Since then, the National Organization of Medical Consumables Joint Procurement Platform issued the "National Organization of Orthopedic Spine Consumables Centralized Procurement Announcement", indicating that after coronary stents and orthopedic artificial joints, orthopedic spinal consumables have officially become the third category of high-value products included in the national centralized procuremen.
consumable.

Since then, the National Organization of Medical Consumables Joint Procurement Platform issued the "National Organization of Orthopedic Spine Consumables Centralized Procurement Announcement", indicating that after coronary stents and orthopedic artificial joints, orthopedic spinal consumables have officially become the third category of high-value products included in the national centralized procuremen.
consumable.

In addition to the centralized procurement of medical device consumables, the original research formed by the centralized procurement of national drugs with a large amount of drugs is gradually included in the scope of centralized procurement of drugs with "large clinical dosage and high procurement amount", covering all kinds of drugs that are clinically necessary and of reliable quality and are marketed in Chin.
Consumables have made imported products experience a huge impact on price:

In addition to the centralized procurement of medical device consumables, the original research formed by the centralized procurement of national drugs with a large amount of drugs is gradually included in the scope of centralized procurement of drugs with "large clinical dosage and high procurement amount", covering all kinds of drugs that are clinically necessary and of reliable quality and are marketed in Chin.
Consumables have made imported products experience a huge impact on price:

In the fourth batch of centralized collection, the price of AstraZeneca's gastric ulcer treatment drug esomeprazole enteric-coated tablets (20mg/tablet) dropped from 9 yuan to 3 yua.

In the fourth batch of centralized collection, the price of AstraZeneca's gastric ulcer treatment drug esomeprazole enteric-coated tablets (20mg/tablet) dropped from 9 yuan to 3 yua.

In the fifth batch of centralized procurement, the main drug form of centralized procurement is injection, accounting for 70% of the purchase amoun.
Paclitaxel injection, oxaliplatin injection, budesonide inhalation, esomeprazole injection, levofloxacin sodium chloride injection, docetaxel injection and other varieties with large clinical dosage were included in the collectio.

In the fifth batch of centralized procurement, the main drug form of centralized procurement is injection, accounting for 70% of the purchase amoun.
Paclitaxel injection, oxaliplatin injection, budesonide inhalation, esomeprazole injection, levofloxacin sodium chloride injection, docetaxel injection and other varieties with large clinical dosage were included in the collectio.

In the seventh batch of centralized procurement, there were 28 companies (27 imitation companies + 1 original research company) bidding on the same stage for the injection formulation of omeprazol.
In the end, 10 companies won the bid, and the original pharmaceutical company AstraZeneca was ou.
The winning bid price of Pfizer's original research drug tigecycline for injection was 4190 yuan/box (50mg*10 sticks), a drop of more than 85% from the highest effective declared pric.

In the seventh batch of centralized procurement, there were 28 companies (27 imitation companies + 1 original research company) bidding on the same stage for the injection formulation of omeprazol.
In the end, 10 companies won the bid, and the original pharmaceutical company AstraZeneca was ou.
The winning bid price of Pfizer's original research drug tigecycline for injection was 4190 yuan/box (50mg*10 sticks), a drop of more than 85% from the highest effective declared pric.

The national centralized procurement should not only save the medical insurance fund, but also ensure the quality and supply, so as to benefit the patient.
According to incomplete statistics, there are more than 70 kinds of chemical drugs that have not yet been included in the centralized procurement and over-evaluation of more than 4 companies, and there is a high probability that there will be more than 90 kinds by the end of the year; more than 4 pharmaceutical companies have 3 kinds of biosimilars, They are bevacizumab, trastuzumab and adalimumab respectivel.
The market size of bevacizumab in public medical institutions alone has exceeded 5 billion yuan, plus trastuzumab and adalimuma.

The national centralized procurement should not only save the medical insurance fund, but also ensure the quality and supply, so as to benefit the patient.
According to incomplete statistics, there are more than 70 kinds of chemical drugs that have not yet been included in the centralized procurement and over-evaluation of more than 4 companies, and there is a high probability that there will be more than 90 kinds by the end of the year; more than 4 pharmaceutical companies have 3 kinds of biosimilars, They are bevacizumab, trastuzumab and adalimumab respectivel.
The market size of bevacizumab in public medical institutions alone has exceeded 5 billion yuan, plus trastuzumab and adalimuma.

Some industry experts predict that according to the previous centralized procurement situation and the national normalized and institutionalized centralized procurement policy requirements, the eighth batch of national centralized procurement in the future will most likely be concentrated in the fields of chemical drugs and biosimilars, traditional Chinese medicine, medical Instruments and consumables follo.

Some industry experts predict that according to the previous centralized procurement situation and the national normalized and institutionalized centralized procurement policy requirements, the eighth batch of national centralized procurement in the future will most likely be concentrated in the fields of chemical drugs and biosimilars, traditional Chinese medicine, medical Instruments and consumables follo.

Today, new technologies, new materials, new products, and new formats of medical care in China are emerging one after anothe.
The scale and benefits of China's medical industry have shown explosive growth, and the industrial ecology also has the strength of international competitio.

Today, new technologies, new materials, new products, and new formats of medical care in China are emerging one after anothe.
The scale and benefits of China's medical industry have shown explosive growth, and the industrial ecology also has the strength of international competitio.

Promote the transformation and upgrading of domestic pharmaceutical equipment enterprises to high-quality development as soon as possible, and then participate in the competition in the international pharmaceutical market; save medical insurance funds and patient drug fees, and lay a financial foundation for the reform of medical service prices, so as to realize the purpose of medical reform of "vacating the cage and changing the bird.

Promote the transformation and upgrading of domestic pharmaceutical equipment enterprises to high-quality development as soon as possible, and then participate in the competition in the international pharmaceutical market; save medical insurance funds and patient drug fees, and lay a financial foundation for the reform of medical service prices, so as to realize the purpose of medical reform of "vacating the cage and changing the bird.